Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897855003> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2897855003 abstract "Accumulation of amyloid-β (Aβ) and neurofibrillary tangles are Alzheimer's disease (AD) associated neuropathologies. Gantenerumab is a fully human anti-Aβ monoclonal antibody that binds, and promotes removal of, aggregated Aβ. In the SCarlet RoAD study (SR; NCT01224106), gantenerumab showed a dose-dependent effect on CSF tau species. Marguerite RoAD (MR; NCT02051608) was a Phase 3 randomized, double-blind, placebo-controlled, efficacy and safety study of low doses of gantenerumab in patients with mild AD. Following SR futility analysis, the double-blind part of MR was terminated and converted into an open-label extension. CSF biomarker data from the double-blind part are presented here. In MR, patients were randomized to receive monthly subcutaneous injections of placebo or gantenerumab. Patients receiving gantenerumab started at 105 mg and up-titrated to 225 mg at Week 28 if an MRI scan confirmed no significant amyloid-related imaging abnormalities. At screening, evidence of amyloid pathology (CSF Aβ1–42 ≤ 700pg/mL) was required. CSF samples were collected at screening, Week 52 (optional), and Week 104/early termination. Aβ1–40, Aβ1–42, total-tau (tTau) and phosphorylated-tau (pTau) levels were assayed using Elecsys® immunoassays. MR enrolled 389 patients; of these, 387 received study treatment and 84 had ≥1 post-baseline CSF sample. Table 1 shows comparable baseline values between arms. Tables 2 and 3 show preliminary data for median percentage changes from baseline to Week 52 and Week 104. For Aβ1–42, a median increase was seen in the gantenerumab arm with a decrease in the placebo arm. Aβ1–40 showed similar percentage decreases in placebo and gantenerumab at Week 52 with a larger percentage decrease in the gantenerumab arm at Week 104. For tTau and pTau, a larger percentage decrease was seen in the gantenerumab arm versus placebo. No biomarker showed a statistically significant difference between study arms. Percentage changes from baseline in Aβ1–42, tTau, and pTau suggest gantenerumab has an effect on CSF biomarkers of AD pathology after 104 weeks of low-dose treatment. These percentage changes in biomarkers were consistent with those in SR. These findings will be further explored in our ongoing Phase 3 program using higher doses of gantenerumab." @default.
- W2897855003 created "2018-10-26" @default.
- W2897855003 creator A5002320307 @default.
- W2897855003 creator A5018749214 @default.
- W2897855003 creator A5026149226 @default.
- W2897855003 creator A5031283026 @default.
- W2897855003 creator A5037459780 @default.
- W2897855003 creator A5043928332 @default.
- W2897855003 creator A5050015669 @default.
- W2897855003 creator A5051452074 @default.
- W2897855003 creator A5060199728 @default.
- W2897855003 creator A5068308578 @default.
- W2897855003 creator A5072019664 @default.
- W2897855003 date "2018-07-01" @default.
- W2897855003 modified "2023-10-16" @default.
- W2897855003 title "O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY" @default.
- W2897855003 doi "https://doi.org/10.1016/j.jalz.2018.06.2379" @default.
- W2897855003 hasPublicationYear "2018" @default.
- W2897855003 type Work @default.
- W2897855003 sameAs 2897855003 @default.
- W2897855003 citedByCount "6" @default.
- W2897855003 countsByYear W28978550032018 @default.
- W2897855003 countsByYear W28978550032020 @default.
- W2897855003 countsByYear W28978550032022 @default.
- W2897855003 countsByYear W28978550032023 @default.
- W2897855003 crossrefType "journal-article" @default.
- W2897855003 hasAuthorship W2897855003A5002320307 @default.
- W2897855003 hasAuthorship W2897855003A5018749214 @default.
- W2897855003 hasAuthorship W2897855003A5026149226 @default.
- W2897855003 hasAuthorship W2897855003A5031283026 @default.
- W2897855003 hasAuthorship W2897855003A5037459780 @default.
- W2897855003 hasAuthorship W2897855003A5043928332 @default.
- W2897855003 hasAuthorship W2897855003A5050015669 @default.
- W2897855003 hasAuthorship W2897855003A5051452074 @default.
- W2897855003 hasAuthorship W2897855003A5060199728 @default.
- W2897855003 hasAuthorship W2897855003A5068308578 @default.
- W2897855003 hasAuthorship W2897855003A5072019664 @default.
- W2897855003 hasConcept C126322002 @default.
- W2897855003 hasConcept C142724271 @default.
- W2897855003 hasConcept C185592680 @default.
- W2897855003 hasConcept C204787440 @default.
- W2897855003 hasConcept C27081682 @default.
- W2897855003 hasConcept C2777633098 @default.
- W2897855003 hasConcept C2779134260 @default.
- W2897855003 hasConcept C2779651940 @default.
- W2897855003 hasConcept C2781197716 @default.
- W2897855003 hasConcept C2989005 @default.
- W2897855003 hasConcept C2991744798 @default.
- W2897855003 hasConcept C3019447875 @default.
- W2897855003 hasConcept C55493867 @default.
- W2897855003 hasConcept C71924100 @default.
- W2897855003 hasConcept C90924648 @default.
- W2897855003 hasConceptScore W2897855003C126322002 @default.
- W2897855003 hasConceptScore W2897855003C142724271 @default.
- W2897855003 hasConceptScore W2897855003C185592680 @default.
- W2897855003 hasConceptScore W2897855003C204787440 @default.
- W2897855003 hasConceptScore W2897855003C27081682 @default.
- W2897855003 hasConceptScore W2897855003C2777633098 @default.
- W2897855003 hasConceptScore W2897855003C2779134260 @default.
- W2897855003 hasConceptScore W2897855003C2779651940 @default.
- W2897855003 hasConceptScore W2897855003C2781197716 @default.
- W2897855003 hasConceptScore W2897855003C2989005 @default.
- W2897855003 hasConceptScore W2897855003C2991744798 @default.
- W2897855003 hasConceptScore W2897855003C3019447875 @default.
- W2897855003 hasConceptScore W2897855003C55493867 @default.
- W2897855003 hasConceptScore W2897855003C71924100 @default.
- W2897855003 hasConceptScore W2897855003C90924648 @default.
- W2897855003 hasIssue "7S_Part_4" @default.
- W2897855003 hasLocation W28978550031 @default.
- W2897855003 hasOpenAccess W2897855003 @default.
- W2897855003 hasPrimaryLocation W28978550031 @default.
- W2897855003 hasRelatedWork W1483886510 @default.
- W2897855003 hasRelatedWork W1996533448 @default.
- W2897855003 hasRelatedWork W2083984027 @default.
- W2897855003 hasRelatedWork W2098565003 @default.
- W2897855003 hasRelatedWork W2419292533 @default.
- W2897855003 hasRelatedWork W2548509799 @default.
- W2897855003 hasRelatedWork W2553110008 @default.
- W2897855003 hasRelatedWork W2989446795 @default.
- W2897855003 hasRelatedWork W3091047728 @default.
- W2897855003 hasRelatedWork W4236949159 @default.
- W2897855003 hasVolume "14" @default.
- W2897855003 isParatext "false" @default.
- W2897855003 isRetracted "false" @default.
- W2897855003 magId "2897855003" @default.
- W2897855003 workType "article" @default.